Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine

被引:45
|
作者
Tano, Eric [1 ]
San Martin, Stephanie [1 ]
Girgis, Stephen [1 ]
Martinez-Fernandez, Yadira [2 ]
Vegas, Carolina Sanchez [3 ]
机构
[1] Nicklaus Childrens Hosp, Dept Grad Med Educ, 3100 SW 62 Ave, Miami, FL 33155 USA
[2] Nicklaus Childrens Hosp, Inst Heart, Miami, FL 33155 USA
[3] Nicklaus Childrens Hosp, Div Infect Dis, Miami, FL 33155 USA
关键词
BNT162b2; COVID-19; vaccine; myocarditis; pericarditis; MYOPERICARDITIS;
D O I
10.1093/jpids/piab060
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
On May 10, 2021, the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was expanded to include adolescents (May 10, 2021. https://www.fda.gov/newsevents/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use). We describe clinical characteristics of 8 adolescents who presented over the course of 36 days to Nicklaus Children's Hospital with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine.
引用
收藏
页码:962 / 966
页数:5
相关论文
共 50 条